Plain-English translation of NCT07688460 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new, highly sensitive blood test to monitor how well works for Alzheimer's disease. is an antibody medication designed to slow cognitive decline in people with early Alzheimer's. Researchers want to see if this new blood test can accurately track the medication's effectiveness by measuring specific Alzheimer's markers in your blood.
Current methods for monitoring how well Alzheimer's treatments are working can be complicated or not sensitive enough. This trial aims to develop a better blood test that could help doctors see more clearly whether the treatment is helping and adjust care accordingly.
You likely qualify if…
You likely don't qualify if…
You will receive treatment according to standard Alzheimer's care protocols. Throughout your participation, you'll have scheduled visits where researchers will draw blood samples to measure Alzheimer's-related markers using the new blood test technology. The study will track how these markers change over time and compare them with your clinical outcomes to see how well the treatment is working for you.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China